



PATENT

Case Docket No. BURNHAM.004A
Date: March 10, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Reed et al.
Appl. No. : 10/735,418
Filed : December 11, 2003
For : CONVERSION OF
APOPTOTIC PROTEINS
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 10, 2004

(Date)

Jennifer A. Haynes, Ph.D., Reg. No. 48,868

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with twenty-one (21) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Jennifer A. Haynes, Ph.D.

Registration No. 48,868

Agent of Record

Customer No. 20,995

(415) 954-4114

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Reed et al.
App. No. : 10/735,418
Filed : December 11, 2003
For : CONVERSION OF APOPTOTIC PROTEINS
Examiner : Unknown
Group Art Unit : Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 21 references that are also enclosed.

This Information Disclosure Statement is being filed with an RCE or within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By:

Jennifer A. Haynes, Ph. D.
Registration No. 48,868
Agent of Record
Customer No. 20,995
(415) 954-4114

Dated: Mar. 10, 2004



FORM PTO-1449 MAR 15 2004	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. BURNHAM.004A	APPLICATION NO. 10/735,418
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Reed et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE December 11, 2003	GROUP Unknown

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
1.	Bohm et al., "The 5'-untranslated region of p23 mRNA from the Ehrlich ascites tumor is involved in translation control of the growth related protein p23" 1991, Biomed Biochim Acta 50:1193; 174:130
2.	Buolamwini, "Novel anticancer drug discovery" 1999, Curr Opin Chem Biol, 3:500-509
3.	Cheng et al., "Functional redundancy of Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis" 1997, EMBO J 16:1865
4.	Cheng et al., "Conversion of Bcl-2 to a Bax-like Death Effector by Caspases" 1997, Science 278:1966-1968
5.	Degterev et al., "Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-X _L " 2001, Nat Cell Bio 3:173-182
6.	Del Bello et al., "Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells" 2001, Oncogene 20:4591-4595
7.	Enyedy et al., "Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening" 2001, J Med Chem 44:4313-4324
8.	Fadeel et al., "Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myloid leukemia cells" 1999, Leukemia 13:719-728
9.	Finnegan et al., "Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions" 2001, Br J Cancer 85:115-121
10.	Fujita et al., "Involvement of Bcl-2 Cleavage in the Acceleration of VP-16-Induced U937 Cell Apoptosis" 1998, Biochem Biophys Res Commun 246:484-488

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



 FORM PTO-1499 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE MAR 15 2004 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BURNHAM.004A	APPLICATION NO. 10/735,418
	APPLICANT Reed et al.	
	FILING DATE December 11, 2003	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
11	Grandgirard et al., "Alphaviruses induce apoptosis in Bcl-2 overexpressing cells; evidence for a caspase-mediated, proteolytic inactivation of Bcl-2" 1998, EMBO J 17:1268-1278
12	Lewis et al., "Inhibition of virus-induced neuronal apoptosis by Bax" 1999, Nat Med 5:832-835
13	Li et al., "Molecular Determinants of AHPN (CD437)-Induced Growth Arrest and Apoptosis in Human Lung Cancer Cell Lines" 1998, Mol Cell Biol 18:4719
14	Li et al., "Cytochrome c Release and Apoptosis Induced by Mitochondrial Targeting of Nuclear Orphan Receptor TR3" 2000, Science 289:1159
15	Liu et al., "Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the Immediate-early gene nur77" 1994, Nature 367:281
16	Reed, John C. "Bcl-2 Family Proteins: Regulators of Apoptosis and Chemoresistance in Hematologic Malignancies" Sem Hematol, 1997, 34:9-19;
17	Tzung et al., "Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3" 2001, Nat Cell Biol 3:183-191
18	Uemura and Chang, "Antisense TR3 Orphan Receptor Can Increase Prostate Cancer Cell Viability with Etoposide Treatment" 1998, Endocrinology 129:2329
19	Wei et al., "Apoptosis of nur77/N10-Transgenic Thymocytes Involves the Fas/Fas Ligand Pathway" Proc Natl Acad Sci USA 93:5533
20	Woronicz et al., "Requirement for the Orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas" 1994, Nature 367:277
21	Young et al., "Tumor-Promoting Phorbol Ester-Induced Cell Death and Gene Expression in a Human Prostate Denocarcinoma Cell Line" 1994, Oncol Res. 6:203

W:\DOCS\JAH\JAH-7156.DOC
031004

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.